Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the ...
Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a diversified company focused on the development of precision diagnostic consumer products and the advancement of intellectual ...
Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer ...
OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or the “Company”), the world leader in listeria-based cancer ...
The U.S. Supreme Court declined to hear Citigroup’s appeal, allowing a $1B fraud lawsuit tied to Oceanografia’s collapse to ...
Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately ...
Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M –– Unaudited 2025 total product and royalty revenue of ...
AI clinical conversation platform Abridge is partnering with health information network Availity to launch a real-time prior ...
The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025–2034), mainly attributed to the launch of upcoming therapies such as ...
Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both ...
Future Pak becomes exclusive U.S. marketer for Mytesi® and Canalevia®-CA1 Meaningful non-dilutive capital enables Jaguar to ...
It’s been a whirlwind year for Venezuela, and it’s just getting started. Over the weekend, the U.S. launched an incursion into Caracas, capturing the nation’s President Nicolás Maduro and leaving the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback